Milestone Pharmaceuticals(MIST) - 2025 Q2 - Quarterly Results

Milestone Strengthens Balance Sheet to Fully Commercialize CARDAMYST if Approved Public Of ering Raised Total Gross Proceeds of up to $170 Million if all Warrants are Exercised $75 Million Royalty Purchase Agreement Payment from RTW Extended Through End of 2025 Exhibit 99.1 Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update FDA Accepted the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray; New PDUFA Target Date of December ...